ImmunoGen (BMV:IMGN *) - Stock Price, News & Analysis

IMGN * Stock Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. More details

IMGN * fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	6/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings are forecast to grow 45.17% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

ImmunoGen, Inc. Competitors

Innovent Biologics

SEHK:1801

HK$60.8b

Swedish Orphan Biovitrum

OM:SOBI

SEK 102.5b

Imeik Technology DevelopmentLtd

SZSE:300896

CN¥60.9b

Shanghai RAAS Blood Products

SZSE:002252

CN¥49.1b

Price History & Performance

Summary of all time highs, changes and price drops for ImmunoGen
Historical stock prices
Current Share Price	US$268.50
52 Week High	US$330.00
52 Week Low	US$101.20
Beta	1.17
11 Month Change	0%
3 Month Change	n/a
1 Year Change	96.13%
33 Year Change	87.76%
5 Year Change	n/a
Change since IPO	595.42%

Recent updates

Shareholder Returns

	IMGN *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	96.1%	0%	0%

Return vs Industry: IMGN * exceeded the MX Biotechs industry which returned -4.3% over the past year.

Return vs Market: IMGN * exceeded the MX Market which returned 6.4% over the past year.

Price Volatility

Is IMGN *'s price volatile compared to industry and market?
IMGN * volatility
IMGN * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: IMGN * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine IMGN *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1980	277	Mark Enyedy	www.immunogen.com

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate.

ImmunoGen, Inc. Fundamentals Summary

How do ImmunoGen's earnings and revenue compare to its market cap?
IMGN * fundamental statistics
Market cap	Mex$142.79b
Earnings (TTM)	-Mex$1.26b
Revenue (TTM)	Mex$4.91b

29.1x

P/S Ratio

-113.7x

P/E Ratio

Is IMGN * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMGN * income statement (TTM)
Revenue	US$287.61m
Cost of Revenue	US$211.62m
Gross Profit	US$76.00m
Other Expenses	US$149.52m
Earnings	-US$73.52m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.27
Gross Margin	26.42%
Net Profit Margin	-25.56%
Debt/Equity Ratio	12.8%

How did IMGN * perform over the long term?

See historical performance and comparison

IMGN * Stock Overview

Rewards

Risk Analysis

ImmunoGen, Inc. Competitors

SEHK:1801

HK$60.8b

OM:SOBI

SEK 102.5b

SZSE:300896

CN¥60.9b

SZSE:002252

CN¥49.1b

Price History & Performance

Recent News & Updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Forecast to breakeven in 2023

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Forecast to breakeven in 2023

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Forecast breakeven date moved forward to 2023

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Forecast to breakeven in 2025

No longer forecast to breakeven

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

Shareholder Returns

Price Volatility

About the Company

ImmunoGen, Inc. Fundamentals Summary

29.1x

-113.7x

Earnings & Revenue